InvestSMART

Integral Diagnostics Limited (ASX:IDX)

ALERT: Price-sensitive ASX Announcement for IDX
Current share price for IDX : $2.300 0.02 (0.88%)+
Announcement
Release
25 Aug 2026 9:13AM
Price at Release
$2.280
Full Release
download
Summary
In the FY26 Annual Report, Integral Diagnostics Limited (IDX) showcases significant financial and operational achievements. The company experienced a substantial revenue increase to $788.7 million, marking a 25.6% rise from the previous year, alongside a 30.3% growth in Operating EBITDA to $164.8 million. This financial success is further highlighted by an Operating NPAT of $47.4 million, a 50.1% rise, and a remarkable 677.4% increase in Statutory NPAT to $22 million. These results reflect successful merger synergies with Capitol Health, improved margins, and strategic expansions, including new practices and an increased role in the National Lung Cancer Screening Program. IDX's operational focus remains on enhancing organic growth and driving efficiencies, as well as maintaining strong governance and sustainable practices.
Key Points
  • Revenue and other income of $788.7 million, up 25.6% from FY25
  • Operating EBITDA of $164.8 million, up 30.3% from FY25
  • Operating NPAT of $47.4 million, up 50.1% from FY25
  • Statutory NPAT of $22 million, up 677.4% from FY25
  • Operating Diluted EPS of 12.6 cents per share, up 23.6% from FY25
  • Improved Group Operating EBITDA margin of 20.9%
  • Successful integration of Capitol Health merger
  • Strong performance in National Lung Cancer Screening Program with 14% share
  • Launch of new practices and expansion in key regions
  • Focus on organic growth and operational efficiencies
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.